Login to Your Account

Phase III Efficacy Failure Sinks Another Glioblastoma Drug

By Marie Powers
Staff Writer

Tuesday, February 26, 2013
The notoriously challenging glioblastoma indication claimed another victim as EMD Serono reported that internally developed integrin inhibitor cilengitide failed to significantly improve overall survival (OS), the primary endpoint, in its Phase III CENTRIC trial investigating the agent when added to standard chemoradiotherapy (temozolomide and radiotherapy).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription